Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sara Estalella-Mendoza"'
Autor:
José Manuel Baena Cañada, Carlos de la Torre Hita, Marta Bernal Gómez, Alicia Campini Bermejo, Salvador Gámez Casado, Lourdes Rodríguez Pérez, Alicia Quílez Cutillas, Julio Calvete Candenas, Sara Estalella Mendoza, Encarnación Benítez Rodríguez
Publikováno v:
Archives of Breast Cancer (2021)
Background: There is a tendency to decrease the intensity of breast cancer treatments, e.g. omitting adjuvant chemotherapy in endocrine-sensitive and HER-2 negative patients. The purpose of this study was to analyse changes in the frequency of the in
Externí odkaz:
https://doaj.org/article/02b41ead8e914ccfb281281d854ff377
Autor:
Encarnación Benítez Rodríguez, Sara Estalella Mendoza, Lourdes Rodríguez Pérez, Carlos de la Torre Hita, Alicia Quílez Cutillas, José M. Baena Cañada, Alicia Campini Bermejo, Julio Calvete Candenas, Salvador Gámez Casado, Marta Bernal Gómez
Publikováno v:
Archives of Breast Cancer (2021)
Background: There is a tendency to decrease the intensity of breast cancer treatments, e.g. omitting adjuvant chemotherapy in endocrine-sensitive and HER-2 negative patients. The purpose of this study was to analyse changes in the frequency of the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::977b9e4f1d3231bc6d2311772d0b3770
https://doi.org/10.32768/abc.202183233-242
https://doi.org/10.32768/abc.202183233-242
Autor:
Encarnación Benítez Rodríguez, Salvador Gámez Casado, Lourdes Rodríguez Pérez, Petra Rosado Varela, Sara Estalella Mendoza, Patricia Ramírez Daffós, Cristina Cortés Carmona, José M. Baena Cañada, Alicia Quílez Cutillas
Publikováno v:
Medicina Clínica. 151:469-475
Resumen Antecedentes y objetivos En el cancer de mama hormonosensible, HER-2 negativo, con ganglios negativos, la presencia de un riesgo genomico bajo permite tratar solo con hormonoterapia adyuvante, obteniendo unas excelentes tasas de supervivencia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2833704692d8d16eba005d5776cc726
https://doi.org/10.1016/j.medcli.2018.01.020
https://doi.org/10.1016/j.medcli.2018.01.020
Autor:
Lourdes Rodríguez Pérez, Sara Estalella Mendoza, Patricia Ramírez Daffós, Encarnación Benítez Rodríguez, Petra Rosado Varela, Alicia Quílez Cutillas, Salvador Gámez Casado, José M. Baena Cañada, Cristina Cortés Carmona
Publikováno v:
Medicina clinica. 151(12)
Background and objectives In endocrine-sensitive, HER2 negative, node negative breast cancer, the presence of a low genomic risk allows treatment with adjuvant endocrine therapy alone, obtaining excellent survival rates. The justification for this st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62959af75e1099c22312956c3b1b0b65
https://pubmed.ncbi.nlm.nih.gov/29501438
https://pubmed.ncbi.nlm.nih.gov/29501438
Autor:
Macarena González-Guerrero, Petra Rosado-Varela, José Manuel Baena-Cañada, Inmaculada Expósito-Álvarez, Encarnación Benítez-Rodríguez, Sara Estalella-Mendoza
Publikováno v:
Medicina Clínica. 140:444-448
Resumen Fundamento y objetivos Estudios previos han relacionado el retraso en iniciar la quimioterapia adyuvante (> 3 meses desde la cirugia) con peor supervivencia. El objetivo de este estudio es analizar el retraso en iniciar quimioterapia y la inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4083d2a388304286f9f353a6dc5e1fd3
https://doi.org/10.1016/j.medcli.2012.03.007
https://doi.org/10.1016/j.medcli.2012.03.007
Autor:
Petra Rosado-Varela, Macarena González-Guerrero, Patricia Ramírez-Daffós, Inmaculada Expósito-Álvarez, Esperanza Arriola-Arellano, Cristina Cortés-Carmona, E. Benítez-Rodríguez, María C. Díaz-Blanco, Antonio Rueda-Ramos, José Manuel Baena-Cañada, Lourdes Solana-Grimaldi, Sara Estalella-Mendoza
Publikováno v:
European Journal of Cancer. 48:3328-3334
Aim of the study The authors analyse the effect of chemotherapy on the use of additional health-care resources and report the clinical and demographic factors associated with such use. Patients and methods In women with breast cancer, eligible to rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b62f295b29ed574d4d4a2c16f22dd18
https://doi.org/10.1016/j.ejca.2012.04.024
https://doi.org/10.1016/j.ejca.2012.04.024
Autor:
José Manuel, Baena-Cañada, Petra, Rosado-Varela, Sara, Estalella-Mendoza, Inmaculada, Expósito-Álvarez, Macarena, González-Guerrero, Encarnación, Benítez-Rodríguez
Publikováno v:
Medicina clinica. 140(10)
Previous studies have related the delay in starting chemotherapy (3 months from date of surgery) with worse survival. The study objective is to analyse the delay in the start of chemotherapy and associated biomedical, sociodemographic and cultural fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9d63496bc5c122854875a259ab3553d6
https://pubmed.ncbi.nlm.nih.gov/22613828
https://pubmed.ncbi.nlm.nih.gov/22613828